Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBITDA (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed EBITDA for 15 consecutive years, with $34.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 894.13% to $34.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.1 million through Dec 2025, up 18922.77% year-over-year, with the annual reading at $120.0 million for FY2025, 1402.92% up from the prior year.
  • EBITDA hit $34.8 million in Q4 2025 for Ani Pharmaceuticals, down from $36.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $36.2 million in Q3 2025 to a low of -$23.7 million in Q4 2021.
  • Historically, EBITDA has averaged $4.2 million across 5 years, with a median of $4.1 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 1554.51% in 2021 and later soared 894.13% in 2025.
  • Year by year, EBITDA stood at -$23.7 million in 2021, then soared by 107.67% to $1.8 million in 2022, then skyrocketed by 269.56% to $6.7 million in 2023, then crashed by 165.09% to -$4.4 million in 2024, then skyrocketed by 894.13% to $34.8 million in 2025.
  • Business Quant data shows EBITDA for ANIP at $34.8 million in Q4 2025, $36.2 million in Q3 2025, and $13.9 million in Q2 2025.